As I prepare to join Advent Health this December, I’ve found myself increasingly drawn back into the nuance of diagnostic timing, evidence interpretation, and the evolving contours of cancer care. This latest case — part clinical, part medical-legal, part new FDA approval and entirely instructive — underscored how much hinges on when and how we act, especially in aggressive diseases like small cell lung cancer. I remain committed to sharing insights that sit at the intersection of medicine, malpractice, research, and systems-level decision-making. Today’s reflection is one of those moments.
Not long ago, I was asked to provide an opinion as an expert witness in a potential medical-legal case involving a patient with small cell lung cancer (SCLC). It was a fascinating situation — not just because of the legal dimensions, but because it touched on one of the rarest treatment windows we encounter in this disease: surgically resectable small cell.
For most of us in oncology, small cell lung cancer exists in a binary world: limited stage versus extensive stage. We don’t typically navigate the classic four stages. Instead, we focus on whether the disease is confined enough for curative intent — usually with concurrent chemoradiotherapy — or whether we’re in palliative territory, where systemic therapy, often chemotherapy combined with immunotherapy, aims to control and delay progression rather than cure.
In limited-stage SCLC, the long-term survival rates hover around 15–20%. But every once in a while, maybe in 5% of all cases, we encounter something unusual — a tiny, incidentally discovered nodule, maybe just 1–3 cm, biopsy-proven small cell, with no nodal involvement and no distant metastasis. If confirmed to be truly localized in the resectable operable patient, these cases open the door to a different approach: surgical resection followed by adjuvant chemotherapy, maybe possibly even avoiding radiation. Survival in this select group? As high as 40–50%, based on retrospective series.
That brings me back to the legal case.
A Case of Timing — and the Uncertainty It Brings
This patient according to the retaining attorney had a small “lung nodule” detected on imaging. But months passed — around four to five — before a definitive diagnosis was made. As you can imagine, in the world of SCLC, that kind of delay is an eternity and can be catastrophic. The question posed was: Would earlier diagnosis have changed anything?
The opposing oncology expert opined that it would not — that this would still be considered limited-stage disease and treated accordingly, so the delay was inconsequential.
But that didn’t initially sit right with me. In truly early, surgically resectable small cell, we deviate from the standard limited-stage protocol. The presence or absence of nodal disease (via negative pet and staging bronchoscopy staging nodal biopsies) and the size of the primary tumor dramatically change our therapeutic playbook. The NCCN guidelines support surgery plus chemo in carefully selected early stage I SCLC — an approach that offers a real better shot at long-term survival.
Unfortunately, after personally reviewing the initial scans, it became clear that the patient’s disease was hilar lymphadenopathy which had progressed during the diagnostic delay. It was not confined as a “small lung nodule” as initially believed by the attorney in a way that surgery followed by chemotherapy would be appropriate, and the staging/treatment outcome likely wouldn’t have changed with earlier diagnosis. I ultimately agreed with the opposing expert’s conclusion. I told the retaining attorney he did not have case that would substantially change the management/treatment approach.
Still, this case was a sharp reminder: catching small cell lung cancer early — really early — changes the game. And those rare windows deserve serious attention for all practicing physicians.
On the Other End of the Spectrum: A New Option for Extensive-Stage SCLC
While that case highlighted a missed opportunity at the earliest stage of disease, another development this month gave us something new for patients at the opposite end of the spectrum — those with extensive-stage small cell.
On October 2, 2025, the FDA approved a new combination: lurbinectedin plus atezolizumab as maintenance therapy for patients whose disease has not progressed after initial platinum-based chemotherapy. The approval was based on the IMforte trial, a randomized phase III study comparing this combination against atezolizumab alone.
The results were significant:
- Progression-free survival (PFS): 46% reduction in risk of progression or death
- Overall survival (OS): 20% reduction in risk of death
- Median OS: 13.0 months (combo) vs. 10.0 months (atezo alone)
Of course, there are trade-offs. Grade 3–4 toxicity was higher with the combination (25% vs. 5.8%), including some treatment-related deaths (notably from sepsis and febrile neutropenia). Treatment discontinuation occurred in 6% of patients on the combination versus 3% with atezo alone. So while this regimen adds a promising option, patient selection and close hematologic/infectious monitoring are key.
Two Sides of the Same Coin
What struck me about this moment — these two events just weeks apart — is how they bookend the treatment landscape for small cell lung cancer.
- On one end, we have a rare but real opportunity for curative surgery in ultra-early-stage disease.
- On the other, we have new maintenance therapy offering improved survival in extensive-stage cases that, not long ago, felt like therapeutic dead-ends.
Although a very uncommon situation, I believe when caught early enough in the absence of nodal disease via pet and bronchoscopy nodal staging biopsies, SCLC may offer a rare but real opportunity for curative surgery plus chemotherapy — a window that closes quickly with delay. And yet, even in advanced-stage disease, the emergence of new treatments like lurbinectedin plus atezolizumab is expanding what we can offer. The lesson here isn’t just about early versus late; it’s about how fast SCLC moves, and how critical it is that our systems, our guidelines, and our clinical thinking evolve just as quickly. Timing may define prognosis — but timely knowledge and action can still shift outcomes.
About the author
Dr. Sajeve Thomas is a distinguished medical professional and a compassionate guide in the field of oncology. With over a decade of dedicated experience as a board-certified medical oncologist/internal medicine specialist, Dr. Thomas has become a trusted expert in the treatment of melanoma, sarcoma, and gastrointestinal conditions. He brings a wealth of expertise to the complex and challenging world of oncology.
Disclosures:
Dr. Thomas serves as a speaker for Bristol Myers Squibb (BMS), Merck, Ipsen, Natera, Immunocore, Pfizer, and SpringWorks. He also receives industry grants in support of numerous clinical trials.